147 related articles for article (PubMed ID: 15899835)
1. The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates.
Wielinga P; Hooijberg JH; Gunnarsdottir S; Kathmann I; Reid G; Zelcer N; van der Born K; de Haas M; van der Heijden I; Kaspers G; Wijnholds J; Jansen G; Peters G; Borst P
Cancer Res; 2005 May; 65(10):4425-30. PubMed ID: 15899835
[TBL] [Abstract][Full Text] [Related]
2. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system.
Chen ZS; Lee K; Walther S; Raftogianis RB; Kuwano M; Zeng H; Kruh GD
Cancer Res; 2002 Jun; 62(11):3144-50. PubMed ID: 12036927
[TBL] [Abstract][Full Text] [Related]
3. 5-amino-4-imidazolecarboxamide riboside potentiates both transport of reduced folates and antifolates by the human reduced folate carrier and their subsequent metabolism.
McGuire JJ; Haile WH; Yeh CC
Cancer Res; 2006 Apr; 66(7):3836-44. PubMed ID: 16585211
[TBL] [Abstract][Full Text] [Related]
4. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis.
Assaraf YG
Drug Resist Updat; 2006; 9(4-5):227-46. PubMed ID: 17092765
[TBL] [Abstract][Full Text] [Related]
5. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions.
Peters GJ; Smitskamp-Wilms E; Smid K; Pinedo HM; Jansen G
Cancer Res; 1999 Nov; 59(21):5529-35. PubMed ID: 10554030
[TBL] [Abstract][Full Text] [Related]
6. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport.
Zeng H; Chen ZS; Belinsky MG; Rea PA; Kruh GD
Cancer Res; 2001 Oct; 61(19):7225-32. PubMed ID: 11585759
[TBL] [Abstract][Full Text] [Related]
7. Intracellular pharmacokinetics of methotrexate polyglutamates in human breast cancer cells. Selective retention and less dissociable binding of 4-NH2-10-CH3-pteroylglutamate4 and 4-NH2-10-CH3-pteroylglutamate5 to dihydrofolate reductase.
Jolivet J; Chabner BA
J Clin Invest; 1983 Sep; 72(3):773-8. PubMed ID: 6193143
[TBL] [Abstract][Full Text] [Related]
8. The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate.
Zhao R; Babani S; Gao F; Liu L; Goldman ID
Clin Cancer Res; 2000 Sep; 6(9):3687-95. PubMed ID: 10999762
[TBL] [Abstract][Full Text] [Related]
9. Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport.
Chen ZS; Robey RW; Belinsky MG; Shchaveleva I; Ren XQ; Sugimoto Y; Ross DD; Bates SE; Kruh GD
Cancer Res; 2003 Jul; 63(14):4048-54. PubMed ID: 12874005
[TBL] [Abstract][Full Text] [Related]
10. Molecular basis of antifolate resistance.
Assaraf YG
Cancer Metastasis Rev; 2007 Mar; 26(1):153-81. PubMed ID: 17333344
[TBL] [Abstract][Full Text] [Related]
11. Lack of an effect of breast cancer resistance protein (BCRP/ABCG2) overexpression on methotrexate polyglutamate export and folate accumulation in a human breast cancer cell line.
Rhee MS; Schneider E
Biochem Pharmacol; 2005 Jan; 69(1):123-32. PubMed ID: 15588721
[TBL] [Abstract][Full Text] [Related]
12. ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates.
Shafran A; Ifergan I; Bram E; Jansen G; Kathmann I; Peters GJ; Robey RW; Bates SE; Assaraf YG
Cancer Res; 2005 Sep; 65(18):8414-22. PubMed ID: 16166320
[TBL] [Abstract][Full Text] [Related]
13. Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1).
Hooijberg JH; Jansen G; Assaraf YG; Kathmann I; Pieters R; Laan AC; Veerman AJ; Kaspers GJ; Peters GJ
Biochem Pharmacol; 2004 Apr; 67(8):1541-8. PubMed ID: 15041471
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo resistance in childhood acute lymphoblastic leukemia: Correlations between BCRP, MRP1, MRP4 and MRP5 ABC transporter expression and intracellular methotrexate polyglutamate accumulation.
Jaramillo AC; Cloos J; Lemos C; Stam RW; Kaspers GJL; Jansen G; Peters GJ
Leuk Res; 2019 Apr; 79():45-51. PubMed ID: 30849662
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of antifolate inhibitors of thymidylate and purine synthesis in human soft tissue sarcoma cell lines with intrinsic resistance to methotrexate.
Li WW; Tong WP; Bertino JR
Clin Cancer Res; 1995 Jun; 1(6):631-6. PubMed ID: 9816025
[TBL] [Abstract][Full Text] [Related]
16. Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivo.
Mauritz R; Peters GJ; Kathmann I; Teshale H; Noordhuis P; Comijn EM; Pinedo HM; Jansen G
Cancer Chemother Pharmacol; 2008 Nov; 62(6):937-48. PubMed ID: 18283461
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a folate transporter in HeLa cells with a low pH optimum and high affinity for pemetrexed distinct from the reduced folate carrier.
Wang Y; Zhao R; Goldman ID
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6256-64. PubMed ID: 15448015
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in the understanding of the mechanism of membrane transport of folates and antifolates.
Sierra EE; Goldman ID
Semin Oncol; 1999 Apr; 26(2 Suppl 6):11-23. PubMed ID: 10598550
[TBL] [Abstract][Full Text] [Related]
19. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter.
Volk EL; Schneider E
Cancer Res; 2003 Sep; 63(17):5538-43. PubMed ID: 14500392
[TBL] [Abstract][Full Text] [Related]
20. Carrier-mediated hepatobiliary transport of a novel antifolate, N-[4-[(2,4-dianninopteridine-6-yl)methyl]-3,4-dihydro-2H-1,4-benzothiazin-7-yl]carbonyl-L-homoglutamic acid, in rats.
Han YH; Kato Y; Watanabe Y; Terao K; Asoh Y; Sugiyama Y
Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):394-400. PubMed ID: 11259322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]